@morgans have an outperform rating on Impedimed (IPD) note from Scott Power follows

Livewire Equities

@morgans have an outperform rating on Impedimed (IPD) note from Scott Power follows. Impedimed (IPD, Outperform, Price Target A$0.22) IPD has announced that the American Medical Association (AMA) has made a recommendation to accept the addition of Category I CPT code 937XX2 and delete Category III code 0239T for IPD's device/technology. The decision should become effective from 1 January 2015, which is 12 months earlier than we had expected and is a significant milestone.For those investors with a higher risk profile we suggest buying IPD. Our underlying DCF valuation is A$0.30 and we had set our price target at A$0.22 which we believe will be exceeded today


About this contributor

Livewire Equities

Livewire Equities

, Livewire

The Livewire Equities feed brings you a range of insights that relate to Australian equities

Expertise

No areas of expertise

equities life sciences ipd

Comments

Please sign in to comment on this wire.